CD1 and iNKT cells mediate immune responses against the GBS hemolytic lipid toxin induced by a non-toxic analog
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011490 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Anna Furuta und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America. Hauptthemen laut MEDLINE: Natural Killer T-Cells, Streptococcal Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, FEDER/Junta de Andalucía-Consejería de Transformación Económica, Industria.
Abstract (Originalsprache)
Although hemolytic lipids have been discovered from many human pathogens including Group B Streptococcus (GBS), strategies that neutralize their function are lacking. GBS is a leading cause of pregnancy-associated neonatal infections, and adult GBS infections are on the rise. The GBS hemolytic lipid toxin or granadaene, is cytotoxic to many immune cells including T and B cells. We previously showed that mice immunized with a synthetic nontoxic analog of granadaene known as R-P4 had reduced bacterial dissemination during systemic infection. However, mechanisms important for R-P4 mediated immune protection was not understood. Here, we show that immune serum from R-P4 -immunized mice facilitate GBS opsonophagocytic killing and protect naïve mice from GBS infection. Further, CD4 + T cells isolated from R-P4 -immunized mice proliferated in response to R-P4 stimulation in a CD1d- and iNKT cell-dependent manner. Consistent with these observations, R-P4 immunized mice lacking CD1d or CD1d-restricted iNKT cells exhibit elevated bacterial burden. Additionally, adoptive transfer of iNKT cells from R-P4 vaccinated mice significantly reduced GBS dissemination compared to adjuvant controls. Finally, maternal R-P4 vaccination provided protection against ascending GBS infection during pregnancy. These findings are relevant in the development of therapeutic strategies targeting lipid cytotoxins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, United States of America.
- Department of Global Health, University of Washington, Seattle, Washington, United States of America.
- Department of Organic Chemistry, University of Granada, Granada, Spain.
- Department of Pediatrics, University of Washington, Seattle, Washington, United States of America.
ORCID-Profile: Lakshmi Rajagopal
Förderung
- NIAID NIH HHS
- National Institutes of Health
- FEDER/Junta de Andalucía-Consejería de Transformación Económica, Industria
Zitieren
APA
Furuta, A., Coleman, M., Casares, R., Seepersaud, R., Orvis, A., Brokaw, A., Quach, P., Nguyen, S., Sweeney, E., Sharma, K., Wallen, G., Sanghavi, R., Mateos-Gil, J., Cuerva, J. M., Millán, A., & Rajagopal, L. (2023). CD1 and iNKT cells mediate immune responses against the GBS hemolytic lipid toxin induced by a non-toxic analog. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011490
Vancouver
Furuta A, Coleman M, Casares R, Seepersaud R, Orvis A, Brokaw A, et al. CD1 and iNKT cells mediate immune responses against the GBS hemolytic lipid toxin induced by a non-toxic analog. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011490
BibTeX
@article{Furuta2023,
author = {Furuta, Anna and Coleman, Michelle and Casares, Raquel and Seepersaud, Ravin and Orvis, Austyn and Brokaw, Alyssa and Quach, Phoenicia and Nguyen, Shayla and Sweeney, Erin and Sharma, Kavita and Wallen, Grace and Sanghavi, Rhea and Mateos-Gil, Jaime and Cuerva, Juan Manuel and Millán, Alba and Rajagopal, Lakshmi},
title = {CD1 and iNKT cells mediate immune responses against the GBS hemolytic lipid toxin induced by a non-toxic analog},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011490}
}
EUVIMED